by The global pharmaceutical contract manufacturing market size reached USD 172 billion in 2023 and is expected to hit around USD 330.52 billion by 2033, notable at a CAGR of 6.80% from 2024 to 2033.
Key Points
- North America contributed 36% of market share in 2023.
- Asia-Pacific is estimated to expand the fastest CAGR between 2024 and 2033.
- By service, the pharmaceutical manufacturing services segment has held the largest market share of 33% in 2023.
- By service, the drug development services segment is anticipated to grow at a remarkable CAGR of 8.9% between 2024 and 2033.
- By end-user, the big pharmaceutical companies segment generated over 42% of revenue share in 2023.
- By end-user, the small & mid-sized pharmaceutical companies segment is expected to expand at the fastest CAGR over the projected period.
The market research report on the pharmaceutical contract manufacturing market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of pharmaceutical contract manufacturing products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.
Get a Sample: https://www.precedenceresearch.com/sample/3750
Pharmaceutical Contract Manufacturing Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 6.80% |
| Global Market Size in 2023 | USD 172 Billion |
| Global Market Size by 2033 | USD 330.52 Billion |
| U.S. Market Size in 2023 | USD 43.34 Billion |
| U.S. Market Size by 2033 | USD 84.07 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Service and By End User |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: U.S. Insulation Market Size to Worth USD 19.96 Bn by 2033
The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.
Focusing on the global pharmaceutical contract manufacturing market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the pharmaceutical contract manufacturing market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.
Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of pharmaceutical contract manufacturing products across different countries and applications.
Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.
The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.
This in-depth research report offers valuable insights into the pharmaceutical contract manufacturing market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.
The competitive landscape section of the report provides detailed information on xx market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the pharmaceutical contract manufacturing market.
Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Pharmaceutical Contract Manufacturing Market Companies
- Lonza Group
- Catalent, Inc.
- Patheon (Now part of Thermo Fisher Scientific)
- Recipharm AB
- Boehringer Ingelheim
- Dr. Reddy’s Laboratories
- Jubilant Life Sciences
- Fareva
- Vetter Pharma
- Evonik Industries
- WuXi AppTec
- Pfizer CentreOne
- Almac Group
- AbbVie Contract Manufacturing
- Samsung Biologics
Segments Covered in the Report
By Service
- Pharmaceutical Manufacturing Services
- Pharmaceutical API Manufacturing Services
- Pharmaceutical FDF Manufacturing Services
- Drug Development Services
- Biologic Manufacturing Services
- Biologic API Manufacturing Services
- Biologic FDF Manufacturing Services
By End User
- Big Pharmaceutical Companies
- Small & Mid-Sized Pharmaceutical Companies
- Generic Pharmaceutical Companies
- Other End Users (Academic Institutes, Small CDMOs, and CROs)
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pharmaceutical Contract Manufacturing Market
5.1. COVID-19 Landscape: Pharmaceutical Contract Manufacturing Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pharmaceutical Contract Manufacturing Market, By Service
8.1. Pharmaceutical Contract Manufacturing Market, by Service, 2024-2033
8.1.1. Pharmaceutical Manufacturing Services
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Pharmaceutical API Manufacturing Services
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Pharmaceutical FDF Manufacturing Services
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Drug Development Services
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Biologic Manufacturing Services
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Biologic API Manufacturing Services
8.1.6.1. Market Revenue and Forecast (2021-2033)
8.1.7. Biologic FDF Manufacturing Services
8.1.7.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Pharmaceutical Contract Manufacturing Market, By End User
9.1. Pharmaceutical Contract Manufacturing Market, by End User, 2024-2033
9.1.1. Big Pharmaceutical Companies
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Small & Mid-Sized Pharmaceutical Companies
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Generic Pharmaceutical Companies
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Other End Users (Academic Institutes, Small CDMOs, and CROs)
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Pharmaceutical Contract Manufacturing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Service (2021-2033)
10.1.2. Market Revenue and Forecast, by End User (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.1.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.1.4.2. Market Revenue and Forecast, by End User (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.2. Market Revenue and Forecast, by End User (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.4.2. Market Revenue and Forecast, by End User (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.5.2. Market Revenue and Forecast, by End User (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.6.2. Market Revenue and Forecast, by End User (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.4.2. Market Revenue and Forecast, by End User (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.5.2. Market Revenue and Forecast, by End User (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.6.2. Market Revenue and Forecast, by End User (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.2. Market Revenue and Forecast, by End User (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.4.2. Market Revenue and Forecast, by End User (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.5.2. Market Revenue and Forecast, by End User (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.6.2. Market Revenue and Forecast, by End User (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.5.2. Market Revenue and Forecast, by End User (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.5.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.5.4.2. Market Revenue and Forecast, by End User (2021-2033)
Chapter 11. Company Profiles
11.1. Lonza Group
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Catalent, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Patheon (Now part of Thermo Fisher Scientific)
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Recipharm AB
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Boehringer Ingelheim
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Dr. Reddy’s Laboratories
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Jubilant Life Sciences
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Fareva
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Vetter Pharma
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Evonik Industries
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
